Cargando…
A Chemo-Genomic Approach Identifies Diverse Epigenetic Therapeutic Vulnerabilities in MYCN-Amplified Neuroblastoma
Although a rare disease, neuroblastoma accounts for the highest proportion of childhood cancer deaths. There is a lack of recurrent somatic mutations in neuroblastoma embryonal tumours, suggesting a possible role for epigenetic alterations in driving this cancer. While an increasing number of report...
Autores principales: | Krstic, Aleksandar, Konietzny, Anja, Halasz, Melinda, Cain, Peter, Oppermann, Udo, Kolch, Walter, Duffy, David J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097097/ https://www.ncbi.nlm.nih.gov/pubmed/33968920 http://dx.doi.org/10.3389/fcell.2021.612518 |
Ejemplares similares
-
Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance
por: Duffy, David J., et al.
Publicado: (2017) -
MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma
por: Floros, Konstantinos V., et al.
Publicado: (2022) -
Targeting condensin, a vital spot of MYCN-amplified neuroblastoma
por: Tanno, Yuji, et al.
Publicado: (2014) -
Serine–glycine-one-carbon metabolism: vulnerabilities in MYCN-amplified neuroblastoma
por: Zhao, Erhu, et al.
Publicado: (2020) -
LRP8‐mediated selenocysteine uptake is a targetable vulnerability in MYCN‐amplified neuroblastoma
por: Alborzinia, Hamed, et al.
Publicado: (2023)